Work

Phase 2 of trametinib plus radioiodine in RAS-mutant and wild-type, radioiodine-refractory thyroid cancer (ETCTN9446).

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.6089

Authors: Bharat Burman, R. Michael Tuttle, Ravinder K Grewal, Eric Jeffrey Sherman, Shrujal S. Baxi, Laura Boucai, Mona Sabra, Stephanie Fish, Keith S. Pentlow, Sofia Haque, Irina Ostrovnaya, Ronald A Ghossein, Helen X. Chen, John Humm, Michael Anthony Carducci, Steven M. Larson, David G. Pfister, James A Fagin, Alan Loh Ho

Institutions: Memorial Sloan Kettering Cancer Center, National Cancer Institute, Johns Hopkins University, Johns Hopkins Medicine, Sidney Kimmel Comprehensive Cancer Center

Language: English

Topic: Thyroid Cancer Diagnosis and Treatment

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Institutes of Health

OpenAlex ID: W4293074182

Cites:

Cited by: 10

Related to: 10